At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 206 target
Drug / intervention
SHR-1701drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
In Brief
A Phase 1 clinical trial evaluating SHR-1701 for Solid Tumor. Targeting 206 participants across 1 site.
Detailed Summary
The main purpose of this Phase I study is to access the safety and tolerability of SHR-1701 at different dose levels. It is hoped to find out the recommended dose for Phase II/III.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartNov 2018
Primary CompletionDec 2022
TodayJul 2026
First PostedOct 18, 2018
Enrollment StartNov 20, 2018
Primary CompletionDec 31, 2022
TodayJul 1, 2026
Enrollment to primary: 4.1 yearsPosted 7.7 years ago
Interventions
SHR-1701drug
Subjects will receive an intravenous infusion of SHR-1701 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.